Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 4/20 | 0.56 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.56 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.53 |
| ▸ | TLR2 | O60603 | 4/20 | 0.46 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.44 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 8/20 | 0.42 |
| ▸ | CA2 | P00918 | 8/20 | 0.42 |
| ▸ | CA9 | Q16790 | 7/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 3/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.42 |
| ▸ | CA3 | P07451 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | CA6 | P23280 | 2/20 | 0.42 |
| ▸ | CA5A | P35218 | 2/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11299536 | 1.00 | LPAR1 (0.56) | LPAR1LPAR3LPAR2TLR2DNM1 | |
| SCHEMBL11299539 | 1.00 | LPAR1 (0.56) | LPAR1LPAR3LPAR2TLR2DNM1 | |
| SCHEMBL16475728 | 1.00 | LPAR1 (0.56) | LPAR1LPAR3LPAR2TLR2DNM1 | |
| SCHEMBL11299532 | 1.00 | LPAR1 (0.56) | LPAR1LPAR3LPAR2TLR2DNM1 | |
| SCHEMBL17184093 | 1.00 | LPAR1 (0.56) | LPAR1LPAR3LPAR2TLR2DNM1 | |
| SCHEMBL8912777 | 0.92 | LPAR1 (0.48) | LPAR1LPAR3LPAR2PLA2G2CUSP2 | |
| SCHEMBL26366389 | 0.91 | LPAR1 (0.49) | LPAR1LPAR3LPAR2 | |
| SCHEMBL1077368 | 0.88 | ALDH1A1 (0.55) | LPAR1LPAR3 | |
| SCHEMBL10550605 | 0.87 | PRKD3 (0.55) | LPAR1LPAR3LPAR2PLA2G2CUSP2 | |
| SCHEMBL9716262 | 0.87 | PRKD3 (0.55) | LPAR1LPAR3LPAR2PLA2G2CUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025056466-A1 | POLYVINYLPYRROLIDONE STABILIZING AGENTS, COMPOSITIONS, USES, AND MANUFACTURING METHODS THEREOF | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2025-03-20 | — | — | WO | disclosed |
| EP-2567693-B1 | Lipid encapsulated interfering RNA | PROTIVA BIOTHERAPEUTICS INC (CA) | 2015-10-21 | — | — | EP | disclosed |
| EP-2567693-B1 | Lipid encapsulated interfering RNA | PROTIVA BIOTHERAPEUTICS INC (CA) | 2015-10-21 | — | — | EP | disclosed |
| US-8936942-B2 | Polyethyleneglycol-modified lipid compounds and uses thereof | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2015-01-20 | — | — | US | disclosed |
| US-8936942-B2 | Polyethyleneglycol-modified lipid compounds and uses thereof | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2015-01-20 | — | — | US | disclosed |
| US-8936942-B2 | Polyethyleneglycol-modified lipid compounds and uses thereof | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2015-01-20 | — | — | US | disclosed |
| EP-1648519-B1 | LIPID ENCAPSULATED INTERFERING RNA | PROTIVA BIOTHERAPEUTICS INC (CA) | 2014-10-08 | — | — | EP | disclosed |
| EP-1648519-B1 | LIPID ENCAPSULATED INTERFERING RNA | PROTIVA BIOTHERAPEUTICS INC (CA) | 2014-10-08 | — | — | EP | disclosed |
| EP-2567693-A1 | Lipid encapsulated interfering RNA | Protiva Biotherapeutics Inc. (CA) | 2013-03-13 | — | — | EP | disclosed |
| EP-1664316-B1 | POLYETHYLENEGLYCOL-MODIFIED LIPID COMPOUNDS AND USES THEREOF | PROTIVA BIOTHERAPEUTICS INC (CA) | 2012-08-29 | — | — | EP | disclosed |
| US-7803397-B2 | Polyethyleneglycol-modified lipid compounds and uses thereof | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2010-09-28 | — | — | US | disclosed |
| US-7803397-B2 | Polyethyleneglycol-modified lipid compounds and uses thereof | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2010-09-28 | — | — | US | disclosed |
| US-20060240093-A1 | LIPID ENCAPSULATED INTERFERING RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2006-10-26 | — | — | US | disclosed |
| WO-2006074546-A1 | LIPID ENCAPSULATED INTERFERING RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2006-07-20 | — | — | WO | disclosed |
| EP-1664316-A1 | POLYETHYLENEGLYCOL-MODIFIED LIPID COMPOUNDS AND USES THEREOF | Protiva Biotherapeutics Inc. (CA) | 2006-06-07 | — | — | EP | disclosed |
| EP-1648519-A2 | LIPID ENCAPSULATED INTERFERING RNA | Protiva Biotherapeutics Inc. (CA) | 2006-04-26 | — | — | EP | disclosed |
| US-20050175682-A1 | Polyethyleneglycol-modified lipid compounds and uses thereof | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2005-08-11 | — | — | US | disclosed |
| US-20050064595-A1 | Lipid encapsulated interfering RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2005-03-24 | — | — | US | disclosed |
| WO-2005026372-A1 | POLYETHYLENEGLYCOL-MODIFIED LIPID COMPOUNDS AND USES THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2005-03-24 | — | — | WO | disclosed |
| WO-2005007196-A2 | LIPID ENCAPSULATED INTERFERING RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050064595-A1 | Lipid encapsulated interfering RNA | ABHD16A, LDLR, RNASE1 | LPAR1 59/4885LPAR3 40/4885LPAR2 71/4885 |
| US-20050175682-A1 | Polyethyleneglycol-modified lipid compounds and uses thereof | LIPA, PNLIP, PLTP | LPAR1 65/4885LPAR3 88/4885LPAR2 69/4885 |
| US-20060240093-A1 | LIPID ENCAPSULATED INTERFERING RNA | ABHD16A, LDLR, RNASE1 | LPAR1 59/4885LPAR3 40/4885LPAR2 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.